News

Germany’s enmodes won recognition at the recent 2017 Design of Medical Devices Conference in Minneapolis for its RAS-Q technology to help people with pulmonary hypertension (PH). RAS-Q is a respiratory assist device that offers comprehensive, fully portable, cost-effective and protective treatment for PH patients. One week before the April 9-12 conference where RAS-Q won an Emerging…

Movie-goers will be seeing pulmonary hypertension public service announcements at selected theaters in California, Nevada and Washington, beginning today, which is World PH Day. The Phaware Global Association and On the Wall Theater Advertising arranged for the I’m Aware That I’m Rare PSAs to run in 80 Galaxy theaters and IMAX…

SteadyMed announced  it has received a U.S. patent for its PatchPump infusion system for injectable drugs, including Trevyent, the company’s lead candidate as a potential treatment for pulmonary arterial hypertension (PAH). The patent, issued by the U.S. Patent and Trademark Office (No. 14/384,152), includes but is not limited to claims for a pump…

The INOpulse nitric-oxide dispenser improves respiratory and exercise capacity in patients with difficult-to-treat pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF), a Phase 2 trial indicates. Bellerophon Therapeutics, which developed INOpulse, will present the trial results at an  international conference of the American Thoracic Society International Conference in Washington on May 21.

Selexipag improved the condition of Japanese with pulmonary arterial hypertension (PAH), according to a clinical trial. The United States and a number of other countries have approved the therapy, but Japan wanted a clinical trial specifically with Japanese patients before authorizing it. Selexipag is available in the U.S. under the brand…

Pulmonary arterial hypertension (PAH) patients who fail to respond completely to Adcirca (tadalafil) or Viagra (sildenafil) benefit from Letairis (ambrisentan) as an add-on therapy, according to a study. The research, “Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a…

The Pulmonary Hypertension Association of Canada will be trying to persuade medical professionals to pay more attention to pulmonary hypertension (PH) as a possible cause of their patients’ respiratory-related symptoms. The association will start a campaign next month called Sometimes it’s PH to raise awareness practitioners’ awareness of PH. It chose…

Dr. C. Gregory Elliott has won the 2017 American Thoracic Society Public Advisory Roundtable William J. Martin, II Distinguished Achievement Award. This honor recognizes Elliott’s innovative leadership skills, history in public service and passion for his patients. Elliott, a pioneer member of the Pulmonary Hypertension Association (PHA), has made important contributions in…

A form of pulmonary hypertension known as chronic thromboembolic pulmonary hypertension may be under-diagnosed and under-treated, a review of research articles suggests. The study, “An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan,” was published in the European…

A recent National Institutes of Health (NIH) study shows that moderate to vigorous exercise can help reduce hypertension in African-Americans. The observational study, “Physical Activity and Incident Hypertension in African Americans,” was conducted with participants enrolled in the Jackson Heart Study, a large, community-based analysis of cardiovascular disease in…

Researchers have shown that assessing vasculature structures by magnetic resonance imaging (MRI) can retrieve important information and has predictive potential for pulmonary arterial hypertension (PAH) patients. In combination with clinical data, MRI can increase the accuracy of determining PAH severity and outcomes, and improve decisions regarding therapies. The finding, from researchers…

Adcirca (tadalafil) improved the pulmonary arterial hypertension (PAH) of 29 percent of patients in a real-world study in Japan, researchers said. They two-year study also found the treatment to be safe, with acceptable rates of side effects. A real-world study covers a patient group with a wider range of characteristics than…